376 related articles for article (PubMed ID: 17602065)
1. Industry, clinical trials, and the cost of cancer drugs: an investor's perspective.
Fiorino T
J Clin Oncol; 2007 Jul; 25(19):e21-3. PubMed ID: 17602065
[No Abstract] [Full Text] [Related]
2. Ethics in oncology: consulting for the investment industry.
Berlin J; Bruinooge SS; Tannock IF
J Clin Oncol; 2007 Feb; 25(4):444-6. PubMed ID: 17264341
[TBL] [Abstract][Full Text] [Related]
3. Interactions with the investment industry: practical and ethical implications.
American Society of Clinical Oncology
J Clin Oncol; 2007 Jan; 25(3):338-40. PubMed ID: 17235050
[No Abstract] [Full Text] [Related]
4. Financial relationships in economic analyses of targeted therapies in oncology.
Valachis A; Polyzos NP; Nearchou A; Lind P; Mauri D
J Clin Oncol; 2012 Apr; 30(12):1316-20. PubMed ID: 22430267
[TBL] [Abstract][Full Text] [Related]
5. Cancer pathways' target not validated by clinical results.
Ratner M
Nat Biotechnol; 1999 Mar; 17(3):220. PubMed ID: 10096279
[No Abstract] [Full Text] [Related]
6. Deal-making trends in oncology.
Moore K; Walker J
Nat Rev Drug Discov; 2009 Aug; 8(8):604. PubMed ID: 19644466
[No Abstract] [Full Text] [Related]
7. Wall Street and clinical trials.
Steinbrook R
N Engl J Med; 2005 Sep; 353(11):1091-3. PubMed ID: 16162879
[No Abstract] [Full Text] [Related]
8. Stocks' study renews concerns over insider trading on oncology drugs.
Goozner M
J Natl Cancer Inst; 2011 Nov; 103(22):1652-5. PubMed ID: 22025626
[No Abstract] [Full Text] [Related]
9. Papers with industry ties. Classic confounding conflicts.
Evans SJ
BMJ; 2009 Jun; 338():b2397. PubMed ID: 19528117
[No Abstract] [Full Text] [Related]
10. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
11. [Clinical researchers and pharmaceutical industry. Dangerous liaisons].
Roos JC
Ned Tijdschr Geneeskd; 1999 Aug; 143(32):1668-71. PubMed ID: 10494304
[TBL] [Abstract][Full Text] [Related]
12. Drug cost avoidance resulting from cancer clinical trials.
Bredin C; Eliasziw M; Syme R
Contemp Clin Trials; 2010 Nov; 31(6):524-9. PubMed ID: 20840876
[TBL] [Abstract][Full Text] [Related]
13. Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors.
Daly B; Bach PB; Page RD
JAMA Oncol; 2018 Feb; 4(2):255-257. PubMed ID: 29270631
[TBL] [Abstract][Full Text] [Related]
14. A positive step forward, but more needed to maximize cost benefits of new-generation cancer therapies.
Haines IE
J Clin Oncol; 2007 Sep; 25(25):e31-2. PubMed ID: 17761966
[No Abstract] [Full Text] [Related]
15. Conflicts of interest in dermatology.
Williams HC; Naldi L; Paul C; Vahlquist A; Schroter S; Jobling R
Acta Derm Venereol; 2006; 86(6):485-97. PubMed ID: 17106594
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials: the pitfalls of interpretation.
Lokhandwalla Y; Dalvi B
Issues Med Ethics; 1998 Apr; 6(2):47-8. PubMed ID: 15011700
[No Abstract] [Full Text] [Related]
17. India's drug tests.
Padma TV
Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471
[No Abstract] [Full Text] [Related]
18. Profit at a cost?
Nat Cell Biol; 2000 Jul; 2(7):E113. PubMed ID: 10878816
[No Abstract] [Full Text] [Related]
19. Improving the institutional submission and approval process for clinical research protocols in oncology.
Camacho LH; Marubio L; Purdom MA; Leonard D; Hong DS; Moulder S; Pilat SR; Kurzrock R
J Clin Oncol; 2007 Apr; 25(12):1632-3. PubMed ID: 17443009
[No Abstract] [Full Text] [Related]
20. Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology.
Riechelmann RP; Wang L; O'Carroll A; Krzyzanowska MK
J Clin Oncol; 2007 Oct; 25(29):4642-7. PubMed ID: 17925561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
